IntraOp Medical

The exciting news from our partners at CHUV | Lausanne university hospital keeps coming! Based at Lausanne University Hospital and University of Lausanne in Switzerland, CHUV announced the first randomized Phase II selection trial of FLASH versus conventional radiotherapy for patients with localized carcinomas. This groundbreaking study is the second clinical human trial using Mobetron with electrons, signaling another significant impact on the future of cancer treatment.

Read the story:
https://intraop.com/news-events/second-clinical-human-trial-with-chuv-using-mobetron-with-flash-radiotherapy/


(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.)

IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinoma

IntraOp is excited to share the results for ultra-high dose rate FLASH radiotherapy survival and toxicity in independent murine studies by MD Anderson Cancer Center in Houston, TX, and CHUV | Lausanne university hospital in Lausanne, Switzerland, made possible by the IntraOp Mobetron with FLASH-IQ.*

This independent study also validates the robustness of the FLASH-IQ platform in reproducible FLASH effects. The study's findings suggest that "... using beam parameters that are known to evoke FLASH effects can lead to responses that are robust and reproducible across machines and institutions..." (Jean Bourhis et al.).

We are proud to support these seminal investigational studies with the stability, linearity, and reproducibility of IntraOp Mobetron with FLASH-IQ.


https://www.mdpi.com/2072-6694/15/7/2121

(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not currently cleared for sale by the US FDA.)

Independent Reproduction of the FLASH Effect on the Gastrointestinal Tract: A Multi-Institutional Comparative Study FLASH radiation therapy (RT) is a promising new paradigm in radiation oncology. However, a major question that remains is the robustness and reproducibility of the FLASH effect when different irradiators are used on animals or patients with different genetic backgrounds, diets, and microbiomes, all....

Come hear Dr. Brabham speak on Electron Therapy for the Precise and Non-Invasive Treatment of Nonmelanoma Skin Cancer. Join us at 12:15 pm CT in booth 222 and discover just how effective IntraOp Electron Therapy for Skin Cancer can be for both your practice and for your patients.

Electron Therapy for Non-Invasive Treatment of Skin Cancer IntraOp is excited to join the American Academy of Dermatology for its AAD Annual Meeting in New Orleans, Louisiana on March 17-21, 2023.

Join us for our Meet the Expert event tomorrow at 12:15 CT in booth 222. Dr. Jeffrey G. Brabham (MD, MBA) will be presenting on Electron Therapy for the Precise and Non-Invasive Treatment of Nonmelanoma Skin Cancer.

Electron Therapy for Non-Invasive Treatment of Skin Cancer IntraOp is excited to join the American Academy of Dermatology for its AAD Annual Meeting in New Orleans, Louisiana on March 17-21, 2023.